Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer.

ABSTRACT:

What is this study about?

This is a summary of the results of an ongoing study called CROWN. In the CROWN study, researchers looked at the effects of two medicines called lorlatinib (Lorbrena) and crizotinib (Xalkori) for people with advanced non-small cell lung cancer (NSCLC) who had not been treated yet. Everyone in the study had changes in a gene called anaplastic lymphoma kinase, or ALK, in their cancer cells. The changes in the ALK gene can make cancer grow. This analysis looked at how well lorlatinib and crizotinib worked and their side effects in people with advanced ALK-positive NSCLC after 5 years.

What did this study find?

After observing people for an average of 5 years, researchers found that more people who took lorlatinib were

SUBMITTER: Solomon BJ 

PROVIDER: S-EPMC11789470 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature